Preoperative Platelet-to-Lymphocyte Ratio (PLR) for Predicting the Survival of Stage I-III Gastric Cancer Patients with a MGC Component
Overview
Biotechnology
General Medicine
Affiliations
Background: The preoperative platelet-to-lymphocyte ratio (PLR) evaluates the prognosis of gastric cancer patients. However, whether preoperative PLR may be used to evaluate the prognosis of mucinous gastric carcinoma (MGC) patients is poorly investigated. The present study evaluated the effect of preoperative PLR on overall survival in gastric cancer patients with a mucinous component.
Methods: A total of 336 MGC were enrolled in this study, and the characteristics of the tumor, including pathological features and clinical data, were retrospectively analyzed.
Results: A high PLR was associated with larger tumor size, advanced tumor invasion, lymph node metastasis, advanced TNM stage, tumor location, total gastrectomy, low hemoglobin level, low albumin level, high fibrinogen level, high platelet level, and high neutrophil-to-lymphocyte ratio (NLR, all 's < 0.05). Multivariate analysis identified age (HR = 1.876; 95% CI 1.361-2.585, < 0.001), TNM stage (HR = 2.350; 95% CI 1.216-4.542, = 0.011), globulin (HR = 1.520; 95% CI 1.067-2.165, = 0.020), total gastrectomy (HR = 0.537; 95% CI 0.373-0.772, = 0.001), and PLR (HR = 1.582; 95% CI 1.066-2.348, = 0.023) as independent prognostic factors for OS.
Conclusion: Preoperative PLR is related to pathological features and may independently evaluate the survival of MGC. Therefore, preoperative PLR may help physicians develop treatment plans and evaluate survival in these patients.
Platelet Lymphocyte Ratio as a Prognosticator in Oral Cancer Patients.
Hamad B, Eltohami Y, Suleiman A J Maxillofac Oral Surg. 2025; 24(1):233-240.
PMID: 39902412 PMC: 11787137. DOI: 10.1007/s12663-023-01959-8.
Qiao H, Feng Y, Han X, Tang H Front Oncol. 2024; 14:1393684.
PMID: 38966070 PMC: 11222396. DOI: 10.3389/fonc.2024.1393684.
Kudou K, Kajiwara S, Motomura T, Yukaya T, Nakanoko T, Kuroda Y J Anus Rectum Colon. 2024; 8(2):118-125.
PMID: 38689779 PMC: 11056533. DOI: 10.23922/jarc.2023-056.
Zeng Q, Wang S, Bai Z, Nie Y, Xu L, Chang D Front Oncol. 2024; 14:1279011.
PMID: 38511137 PMC: 10951101. DOI: 10.3389/fonc.2024.1279011.
Kim J, Sun K Acute Crit Care. 2024; 39(1):146-154.
PMID: 38476067 PMC: 11002612. DOI: 10.4266/acc.2023.01319.